GSK plc (NYSE:GSK) finished Thursday with an addition of $0.35 to close at $35.13, an upside of 1.01 percent. An average of 2,950,820 shares of common stock have been traded in the last five days. There was a fall of -$0.17 in the past week, and it reached a new high 8 times over the past 12 months. The last 20 days have seen an average of 6,387,070 shares traded, while the 50-day average volume stands at 6,032,816.
GSK stock has increased by 2.24% in the last month. The company shares reached their 1-month lowest point of $33.89 on 11/30/22. With the stock rallying to its 52-week high on 04/11/22, shares of the company touched a low of $28.47 and a high of $47.82 in 52 weeks. It has reached a new high 9 times so far this year and lost -21.75% or -$8.97 in price. In spite of this, the price is down -26.53% from the 52-week high.
GSK plc (GSK) has a trailing price-to-earnings (P/E) ratio of 14.70. The stock’s beta is 0.68. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.89, the price-to-book (PB) ratio at 6.52, and the price-to-cash flow ratio at 14.19.
The company has a payout ratio of 4.10%. The company’s most recent quarterly dividend payment was $0.3695 a share, representing a down of -3.52% from $0.3830 last year. Its latest decrease dividend $0.0135 reported on Wednesday November 2 2022.
The quick ratio of GSK plc for the three months ended June 29 was 0.70, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.11 and a total debt to equity ratio of 2.42 for the quarter ending June 29. Its gross profit as reported stood at $30.95 billion compared to revenue of $46.91 billion.
For the three-month period that ended June 29, GSK plc had -$921.0 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $4.38 billion in the quarter, while revenues were shrunk -31.11%. The analyst consensus anticipated GSK plc’s latest quarter earnings to come in at $0.73 per share, but it turned out to be $0.87, a 19.20% surprise. For the quarter, EBITDA amounted to $2.43 billion.
From a technical analysis perspective, let’s take a brief look at GSK plc (GSK) price momentum. RSI 9-day as of the close on 29 December was 49.62%, suggesting the stock is Neutral, with historical volatility in this time frame at 13.30%.
As of today, GSK’s price is $35.10 -0.48% or -$0.17 from its 5-day moving average. GSK is currently trading +1.56% higher than its 20-day SMA and -12.85% lower than its 100-day SMA. However, the stock’s current price level is +12.42% above the SMA50 and -15.76% below the SMA200.
The stochastic %K and %D were 11.17% and 12.50%, respectively, and the average true range (ATR) was 0.62. With the 14-day stochastic at 19.61% and the average true range at 0.68, the RSI (14) stands at 52.64%. The stock has reached -0.08 on the 9-day MACD Oscillator while the 14-day reading was at -0.36.
BofA Securities downgraded GSK plc (NYSE: GSK) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for GSK plc (GSK) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell GSK, while 13 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is GSK’s price target for the next 12 months?
Analysts predict a range of price targets between $30.37 and $61.88, with a median target of $37.92. Taking a look at these predictions, the average price target given by analysts for GSK plc (GSK) stock is $39.52.